<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;ff=20230901160807&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;ff=20230901160807&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Fri, 01 Sep 2023 20:08:08 +0000</lastbuilddate>
<pubDate>Fri, 01 Sep 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Reducing the risks of nuclear war: the role of health professionals†</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37655648/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 1:ehad542. doi: 10.1093/eurheartj/ehad542. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37655648/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37655648</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad542>10.1093/eurheartj/ehad542</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37655648</guid>
<pubDate>Fri, 01 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Kamran Abbasi</dc:creator>
<dc:creator>Parveen Ali</dc:creator>
<dc:creator>Virginia Barbour</dc:creator>
<dc:creator>Kirsten Bibbins-Domingo</dc:creator>
<dc:creator>Marcel G M Olde Rikkert</dc:creator>
<dc:creator>Peng Gong</dc:creator>
<dc:creator>Andy Haines</dc:creator>
<dc:creator>Ira Helfand</dc:creator>
<dc:creator>Richard Horton</dc:creator>
<dc:creator>Bob Mash</dc:creator>
<dc:creator>Arun Mitra</dc:creator>
<dc:creator>Carlos Monteiro</dc:creator>
<dc:creator>Elena N Naumova</dc:creator>
<dc:creator>Eric J Rubin</dc:creator>
<dc:creator>Tilman Ruff</dc:creator>
<dc:creator>Peush Sahni</dc:creator>
<dc:creator>James Tumwine</dc:creator>
<dc:creator>Paul Yonga</dc:creator>
<dc:creator>Chris Zielinski</dc:creator>
<dc:date>2023-09-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Reducing the risks of nuclear war: the role of health professionals†</dc:title>
<dc:identifier>pmid:37655648</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad542</dc:identifier>
</item>
<item>
<title>TAVI or non-TAVI in asymptomatic aortic stenosis, in cardiogenic shock, and in patients with Heyde syndrome?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37652892/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 1;44(33):3105-3109. doi: 10.1093/eurheartj/ehad533.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37652892/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37652892</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad533>10.1093/eurheartj/ehad533</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37652892</guid>
<pubDate>Thu, 31 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-08-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>TAVI or non-TAVI in asymptomatic aortic stenosis, in cardiogenic shock, and in patients with Heyde syndrome?</dc:title>
<dc:identifier>pmid:37652892</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad533</dc:identifier>
</item>
<item>
<title>Structural basis for ion selectivity in potassium-selective channelrhodopsins</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37652010/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>KCR channelrhodopsins (K^(+)-selective light-gated ion channels) have received attention as potential inhibitory optogenetic tools but more broadly pose a fundamental mystery regarding how their K^(+) selectivity is achieved. Here, we present 2.5-2.7 Å cryo-electron microscopy structures of HcKCR1 and HcKCR2 and of a structure-guided mutant with enhanced K^(+) selectivity. Structural, electrophysiological, computational, spectroscopic, and biochemical analyses reveal a distinctive mechanism for...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 24:S0092-8674(23)00863-2. doi: 10.1016/j.cell.2023.08.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">KCR channelrhodopsins (K<sup>+</sup>-selective light-gated ion channels) have received attention as potential inhibitory optogenetic tools but more broadly pose a fundamental mystery regarding how their K<sup>+</sup> selectivity is achieved. Here, we present 2.5-2.7 Å cryo-electron microscopy structures of HcKCR1 and HcKCR2 and of a structure-guided mutant with enhanced K<sup>+</sup> selectivity. Structural, electrophysiological, computational, spectroscopic, and biochemical analyses reveal a distinctive mechanism for K<sup>+</sup> selectivity; rather than forming the symmetrical filter of canonical K<sup>+</sup> channels achieving both selectivity and dehydration, instead, three extracellular-vestibule residues within each monomer form a flexible asymmetric selectivity gate, while a distinct dehydration pathway extends intracellularly. Structural comparisons reveal a retinal-binding pocket that induces retinal rotation (accounting for HcKCR1/HcKCR2 spectral differences), and design of corresponding KCR variants with increased K<sup>+</sup> selectivity (KALI-1/KALI-2) provides key advantages for optogenetic inhibition in vitro and in vivo. Thus, discovery of a mechanism for ion-channel K<sup>+</sup> selectivity also provides a framework for next-generation optogenetics.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37652010/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37652010</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.009>10.1016/j.cell.2023.08.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37652010</guid>
<pubDate>Thu, 31 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Seiya Tajima</dc:creator>
<dc:creator>Yoon Seok Kim</dc:creator>
<dc:creator>Masahiro Fukuda</dc:creator>
<dc:creator>YoungJu Jo</dc:creator>
<dc:creator>Peter Y Wang</dc:creator>
<dc:creator>Joseph M Paggi</dc:creator>
<dc:creator>Masatoshi Inoue</dc:creator>
<dc:creator>Eamon F X Byrne</dc:creator>
<dc:creator>Koichiro E Kishi</dc:creator>
<dc:creator>Seiwa Nakamura</dc:creator>
<dc:creator>Charu Ramakrishnan</dc:creator>
<dc:creator>Shunki Takaramoto</dc:creator>
<dc:creator>Takashi Nagata</dc:creator>
<dc:creator>Masae Konno</dc:creator>
<dc:creator>Masahiro Sugiura</dc:creator>
<dc:creator>Kota Katayama</dc:creator>
<dc:creator>Toshiki E Matsui</dc:creator>
<dc:creator>Keitaro Yamashita</dc:creator>
<dc:creator>Suhyang Kim</dc:creator>
<dc:creator>Hisako Ikeda</dc:creator>
<dc:creator>Jaeah Kim</dc:creator>
<dc:creator>Hideki Kandori</dc:creator>
<dc:creator>Ron O Dror</dc:creator>
<dc:creator>Keiichi Inoue</dc:creator>
<dc:creator>Karl Deisseroth</dc:creator>
<dc:creator>Hideaki E Kato</dc:creator>
<dc:date>2023-08-31</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Structural basis for ion selectivity in potassium-selective channelrhodopsins</dc:title>
<dc:identifier>pmid:37652010</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.009</dc:identifier>
</item>
<item>
<title>Will Induction of Transient Myocyte Proliferation Be a Regenerative Therapy?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37651544/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Sep;133(6):505-507. doi: 10.1161/CIRCRESAHA.123.323399. Epub 2023 Aug 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37651544/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37651544</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323399>10.1161/CIRCRESAHA.123.323399</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37651544</guid>
<pubDate>Thu, 31 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Steven R Houser</dc:creator>
<dc:date>2023-08-31</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Will Induction of Transient Myocyte Proliferation Be a Regenerative Therapy?</dc:title>
<dc:identifier>pmid:37651544</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323399</dc:identifier>
</item>
<item>
<title>Integrated Pathogenesis of Vascular and Cardiac Valve Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37651543/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Sep;133(6):481-483. doi: 10.1161/CIRCRESAHA.123.323451. Epub 2023 Aug 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37651543/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37651543</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323451>10.1161/CIRCRESAHA.123.323451</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37651543</guid>
<pubDate>Thu, 31 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Timothy J Cashman</dc:creator>
<dc:creator>Timothy P Fitzgibbons</dc:creator>
<dc:creator>Chinmay M Trivedi</dc:creator>
<dc:date>2023-08-31</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Integrated Pathogenesis of Vascular and Cardiac Valve Disease</dc:title>
<dc:identifier>pmid:37651543</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323451</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37651541/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Sep;133(6):448-449. doi: 10.1161/RES.0000000000000631. Epub 2023 Aug 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37651541/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37651541</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000631>10.1161/RES.0000000000000631</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37651541</guid>
<pubDate>Thu, 31 Aug 2023 06:00:00 -0400</pubDate>
<dc:date>2023-08-31</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:37651541</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000631</dc:identifier>
</item>
<item>
<title>Beta-blockers in non-obstructive hypertrophic cardiomyopathy: time to ease the heart rate restriction?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37650505/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 31:ehad518. doi: 10.1093/eurheartj/ehad518. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37650505/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37650505</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad518>10.1093/eurheartj/ehad518</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37650505</guid>
<pubDate>Thu, 31 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Adaya Weissler-Snir</dc:creator>
<dc:creator>Harry Rakowski</dc:creator>
<dc:creator>Markus Meyer</dc:creator>
<dc:date>2023-08-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Beta-blockers in non-obstructive hypertrophic cardiomyopathy: time to ease the heart rate restriction?</dc:title>
<dc:identifier>pmid:37650505</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad518</dc:identifier>
</item>
<item>
<title>Optimal Measurement of Coronary Flow and Microvascular Function in Animals and Humans</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37650288/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Aug 31. doi: 10.1161/CIRCRESAHA.123.323341. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37650288/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37650288</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323341>10.1161/CIRCRESAHA.123.323341</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37650288</guid>
<pubDate>Thu, 31 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Lennert Minten</dc:creator>
<dc:creator>Michiel Algoet</dc:creator>
<dc:creator>Johan Bennett</dc:creator>
<dc:creator>Wouter Oosterlinck</dc:creator>
<dc:creator>Bart Meuris</dc:creator>
<dc:creator>Tom Langenaeken</dc:creator>
<dc:creator>Stephanie Bézy</dc:creator>
<dc:creator>Laurine Wouters</dc:creator>
<dc:creator>Jürgen Duchenne</dc:creator>
<dc:creator>Alexis Puvrez</dc:creator>
<dc:creator>Senne de Groote</dc:creator>
<dc:creator>Pierluigi Lesizza</dc:creator>
<dc:creator>Pascal Frederiks</dc:creator>
<dc:creator>Laurens de Vos</dc:creator>
<dc:creator>Tom Adriaenssens</dc:creator>
<dc:creator>Peter Sinnaeve</dc:creator>
<dc:creator>Walter Desmet</dc:creator>
<dc:creator>Keir McCutcheon</dc:creator>
<dc:creator>Christophe Dubois</dc:creator>
<dc:date>2023-08-31</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Optimal Measurement of Coronary Flow and Microvascular Function in Animals and Humans</dc:title>
<dc:identifier>pmid:37650288</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323341</dc:identifier>
</item>
<item>
<title>Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37650264/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: A real-time, targeted, and tailored EHR-based alert system for AHF did not lead to a higher number of overall GDMT prescriptions at discharge. Further refinement and improvement of such alerts and changes to clinician incentives are needed to overcome barriers to the implementation of GDMT during hospitalizations for AHF. GDMT remains suboptimal in this setting, with only one in nine patients being discharged on a comprehensive evidence-based regimen for heart failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 31:ehad512. doi: 10.1093/eurheartj/ehad512. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Patients hospitalized for acute heart failure (AHF) continue to be discharged on an inadequate number of guideline-directed medical therapies (GDMT) despite evidence that inpatient initiation is beneficial. This study aimed to examine whether a tailored electronic health record (EHR) alert increased rates of GDMT prescription at discharge in eligible patients hospitalized for AHF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Pragmatic trial of messaging to providers about treatment of acute heart failure (PROMPT-AHF) was a pragmatic, multicenter, EHR-based, and randomized clinical trial. Patients were automatically enrolled 48 h after admission if they met pre-specified criteria for an AHF hospitalization. Providers of patients in the intervention arm received an alert during order entry with relevant patient characteristics along with individualized GDMT recommendations with links to an order set. The primary outcome was an increase in the number of GDMT prescriptions at discharge.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Thousand and twelve patients were enrolled between May 2021 and November 2022. The median age was 74 years; 26% were female, and 24% were Black. At the time of the alert, 85% of patients were on β-blockers, 55% on angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor, 20% on mineralocorticoid receptor antagonist (MRA) and 17% on sodium-glucose cotransporter 2 inhibitor. The primary outcome occurred in 34% of both the alert and no alert groups [adjusted risk ratio (RR): 0.95 (0.81, 1.12), P = .99]. Patients randomized to the alert arm were more likely to have an increase in MRA [adjusted RR: 1.54 (1.10, 2.16), P = .01]. At the time of discharge, 11.2% of patients were on all four pillars of GDMT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A real-time, targeted, and tailored EHR-based alert system for AHF did not lead to a higher number of overall GDMT prescriptions at discharge. Further refinement and improvement of such alerts and changes to clinician incentives are needed to overcome barriers to the implementation of GDMT during hospitalizations for AHF. GDMT remains suboptimal in this setting, with only one in nine patients being discharged on a comprehensive evidence-based regimen for heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37650264/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37650264</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad512>10.1093/eurheartj/ehad512</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37650264</guid>
<pubDate>Thu, 31 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Lama Ghazi</dc:creator>
<dc:creator>Yu Yamamoto</dc:creator>
<dc:creator>Michael Fuery</dc:creator>
<dc:creator>Kyle O'Connor</dc:creator>
<dc:creator>Sounok Sen</dc:creator>
<dc:creator>Marc Samsky</dc:creator>
<dc:creator>Ralph J Riello</dc:creator>
<dc:creator>Ravi Dhar</dc:creator>
<dc:creator>Joanna Huang</dc:creator>
<dc:creator>Temitope Olufade</dc:creator>
<dc:creator>James McDermott</dc:creator>
<dc:creator>Silvio E Inzucchi</dc:creator>
<dc:creator>Eric J Velazquez</dc:creator>
<dc:creator>Francis Perry Wilson</dc:creator>
<dc:creator>Nihar R Desai</dc:creator>
<dc:creator>Tariq Ahmad</dc:creator>
<dc:date>2023-08-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial</dc:title>
<dc:identifier>pmid:37650264</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad512</dc:identifier>
</item>
<item>
<title>Intranasal 'spray-in-the-pocket' treatment for conversion of supraventricular tachycardia: safe, effective but not definite</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37650261/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 31:ehad502. doi: 10.1093/eurheartj/ehad502. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37650261/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37650261</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad502>10.1093/eurheartj/ehad502</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37650261</guid>
<pubDate>Thu, 31 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Maria Lucia Narducci</dc:creator>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:date>2023-08-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intranasal 'spray-in-the-pocket' treatment for conversion of supraventricular tachycardia: safe, effective but not definite</dc:title>
<dc:identifier>pmid:37650261</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad502</dc:identifier>
</item>
<item>
<title>Reply: Nonculprit Lesion Location and Outcomes From the CULPRIT-SHOCK Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648361/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):e87-e88. doi: 10.1016/j.jacc.2023.06.028.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648361/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37648361</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.028>10.1016/j.jacc.2023.06.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648361</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Uwe Zeymer</dc:creator>
<dc:creator>Taoufik Ouarrak</dc:creator>
<dc:creator>Steffen Desch</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Nonculprit Lesion Location and Outcomes From the CULPRIT-SHOCK Trial</dc:title>
<dc:identifier>pmid:37648361</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.028</dc:identifier>
</item>
<item>
<title>Nonculprit Lesion Location and Outcomes From the CULPRIT-SHOCK Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648360/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):e85. doi: 10.1016/j.jacc.2023.04.062.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648360/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37648360</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.04.062>10.1016/j.jacc.2023.04.062</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648360</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Ahmed Elkaryoni</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Nonculprit Lesion Location and Outcomes From the CULPRIT-SHOCK Trial</dc:title>
<dc:identifier>pmid:37648360</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.04.062</dc:identifier>
</item>
<item>
<title>Mortality Trends After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648359/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In a high-income European country with a fully implemented pPCI strategy, 1-year mortality in pPCI-treated patients with STEMI decreased substantially between 2003 and 2018. Approximately three-quarters of the absolute mortality reduction occurred within the first 30 days after pPCI. These results indicate that optimization of early management of pPCI-treated patients with STEMI offers great opportunities for improving overall survival in contemporary clinical practice.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):999-1010. doi: 10.1016/j.jacc.2023.06.025.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Observational studies have reported that mortality rates after ST-segment elevation myocardial infarction (STEMI) have been stable since 2006 to 2010.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to evaluate the temporal trends in 1-year, 30-day, and 31- to 365-day mortality after STEMI in Western Denmark where primary percutaneous coronary intervention (PCI) has been the national reperfusion strategy since 2003.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using the Western Denmark Heart Registry, the study identified first-time PCI-treated patients undergoing primary PCI (pPCI) for STEMI from 2003 to 2018. Based on the year of pPCI, patients were divided into 4 time-interval groups and followed up for 1 year using the Danish national health registries.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 19,613 patients were included. Median age was 64 years, and 74% were male. One-year mortality decreased gradually from 10.8% in 2003-2006, 10.4% in 2007-2010, 9.1% in 2011-2014, to 7.7% in 2015-2018 (2015-2018 vs 2003-2006: adjusted HR [aHR]: 0.71; 95% CI: 0.62-0.82). The largest absolute mortality decline occurred in the 0- to 30-day period with a 2.3% reduction (aHR: 0.69; 95% CI: 0.59-0.82), and to a lesser extent in the 31- to 365-day period (risk reduction: 1.0%; aHR: 0.71; 95% CI: 0.56-0.90).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In a high-income European country with a fully implemented pPCI strategy, 1-year mortality in pPCI-treated patients with STEMI decreased substantially between 2003 and 2018. Approximately three-quarters of the absolute mortality reduction occurred within the first 30 days after pPCI. These results indicate that optimization of early management of pPCI-treated patients with STEMI offers great opportunities for improving overall survival in contemporary clinical practice.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648359/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37648359</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.025>10.1016/j.jacc.2023.06.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648359</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Pernille Gro Thrane</dc:creator>
<dc:creator>Kevin Kris Warnakula Olesen</dc:creator>
<dc:creator>Troels Thim</dc:creator>
<dc:creator>Christine Gyldenkerne</dc:creator>
<dc:creator>Martin Bødtker Mortensen</dc:creator>
<dc:creator>Steen Dalby Kristensen</dc:creator>
<dc:creator>Michael Maeng</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Mortality Trends After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction</dc:title>
<dc:identifier>pmid:37648359</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.025</dc:identifier>
</item>
<item>
<title>Cardiogenic Shock: Lessons From Hurricanes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648358/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):996-998. doi: 10.1016/j.jacc.2023.06.027.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648358/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37648358</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.027>10.1016/j.jacc.2023.06.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648358</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>David A Baran</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiogenic Shock: Lessons From Hurricanes</dc:title>
<dc:identifier>pmid:37648358</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.027</dc:identifier>
</item>
<item>
<title>Long-Term Outcomes of Cardiogenic Shock Complicating Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648357/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Short- and long-term mortality among patients with AMI-CS is high, with minimal improvement over time. AMI-CS survivors experience significant morbidity, with high risks of readmission and death. Future studies should evaluate interventions to minimize postdischarge morbidity and mortality among AMI-CS survivors.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):985-995. doi: 10.1016/j.jacc.2023.06.026.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiogenic shock secondary to acute myocardial infarction (AMI-CS) is associated with substantial short-term mortality; however, there are limited data on long-term outcomes and trends.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to examine long-term outcomes of AMI-CS patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a population-based, retrospective cohort study in Ontario, Canada of critically ill adult patients with AMI-CS who were admitted to hospitals between April 1, 2009 and March 31, 2019. Outcome data were captured using linked health administrative databases.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 9,789 consecutive patients with AMI-CS from 135 centers were included. The mean age was 70.5 ± 12.3 years, and 67.7% were male. The incidence of AMI-CS was 8.2 per 100,000 person-years, and it increased over the study period. Critical care interventions were common, with 5,422 (55.4%) undergoing invasive mechanical ventilation, 1,425 (14.6%) undergoing renal replacement therapy, and 1,484 (15.2%) receiving mechanical circulatory support. A total of 2,961 patients (30.2%) died in the hospital, and 4,004 (40.9%) died by 1 year. Mortality at 5 years was 58.9%. Small improvements in short- and long-term mortality were seen over the study period. Among survivors to discharge, 2,870 (42.0%) required increased support in care from their preadmission baseline, 3,244 (47.5%) were readmitted to the hospital within 1 year, and 1,047 (15.3%) died within 1 year. The mean number of days at home in the year following discharge was 307.9 ± 109.6.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Short- and long-term mortality among patients with AMI-CS is high, with minimal improvement over time. AMI-CS survivors experience significant morbidity, with high risks of readmission and death. Future studies should evaluate interventions to minimize postdischarge morbidity and mortality among AMI-CS survivors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648357/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37648357</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.026>10.1016/j.jacc.2023.06.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648357</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Lee H Sterling</dc:creator>
<dc:creator>Shannon M Fernando</dc:creator>
<dc:creator>Robert Talarico</dc:creator>
<dc:creator>Danial Qureshi</dc:creator>
<dc:creator>Sean van Diepen</dc:creator>
<dc:creator>Margaret S Herridge</dc:creator>
<dc:creator>Susanna Price</dc:creator>
<dc:creator>Daniel Brodie</dc:creator>
<dc:creator>Eddy Fan</dc:creator>
<dc:creator>Pietro Di Santo</dc:creator>
<dc:creator>Richard G Jung</dc:creator>
<dc:creator>Simon Parlow</dc:creator>
<dc:creator>Mir B Basir</dc:creator>
<dc:creator>Damon C Scales</dc:creator>
<dc:creator>Alain Combes</dc:creator>
<dc:creator>Rebecca Mathew</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:creator>Peter Tanuseputro</dc:creator>
<dc:creator>Benjamin Hibbert</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Long-Term Outcomes of Cardiogenic Shock Complicating Myocardial Infarction</dc:title>
<dc:identifier>pmid:37648357</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.026</dc:identifier>
</item>
<item>
<title>Managing Myocardial Infarction in the Age of Multimorbidity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648356/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):982-984. doi: 10.1016/j.jacc.2023.06.023.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648356/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37648356</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.023>10.1016/j.jacc.2023.06.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648356</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Alexander C Fanaroff</dc:creator>
<dc:creator>Michela Faggioni</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Managing Myocardial Infarction in the Age of Multimorbidity</dc:title>
<dc:identifier>pmid:37648356</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.023</dc:identifier>
</item>
<item>
<title>Temporal Trends in Noncardiovascular Morbidity and Mortality Following Acute Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648355/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Although cardiovascular mortality following MI improved substantially during 2000 to 2017, the risk of noncardiovascular morbidity increased. Moreover, noncardiovascular causes constitute an increasing proportion of post-MI mortality. These findings suggest that further attention on noncardiovascular outcomes is warranted in guidelines and clinical practice and should be considered in the design of future clinical trials.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):971-981. doi: 10.1016/j.jacc.2023.06.024.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Due to improved management, diagnosis, and care of myocardial infarction (MI), patients may now survive long enough to increasingly develop serious noncardiovascular conditions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to test this hypothesis by investigating the temporal trends in noncardiovascular morbidity and mortality following MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We conducted a registry-based nationwide cohort study of all Danish patients with MI during 2000 to 2017. Outcomes were cardiovascular and noncardiovascular mortality, incident cancer, incident renal disease, and severe infectious disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From 2000 to 2017, 136,293 consecutive patients were identified (63.2% men, median age 69 years). The 1-year risk of cardiovascular mortality between 2000 to 2002 and 2015 to 2017 decreased from 18.4% to 7.6%, whereas noncardiovascular mortality decreased from 5.8% to 5.0%. This corresponded to an increase in the proportion of total 1-year mortality attributed to noncardiovascular causes from 24.1% to 39.5%. Furthermore, increases in 1-year risk of incident cancer (1.9%-2.4%), incident renal disease (1.0%-1.6%), and infectious disease (5.5%-9.1%) were observed (all P trend &lt;0.01). In analyses standardized for changes in patient characteristics, the increased risk of cancer in 2015 to 2017 compared with 2000 to 2002 was no longer significant (standardized risk ratios for cancer: 0.99 [95% CI: 0.91-1.07]; renal disease: 1.28 [95% CI: 1.15-1.41]; infectious disease: 1.28 [95% CI: 1.23-1.34]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Although cardiovascular mortality following MI improved substantially during 2000 to 2017, the risk of noncardiovascular morbidity increased. Moreover, noncardiovascular causes constitute an increasing proportion of post-MI mortality. These findings suggest that further attention on noncardiovascular outcomes is warranted in guidelines and clinical practice and should be considered in the design of future clinical trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648355/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37648355</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.024>10.1016/j.jacc.2023.06.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648355</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Daniel Mølager Christensen</dc:creator>
<dc:creator>Jarl Emanuel Strange</dc:creator>
<dc:creator>Mohamad El-Chouli</dc:creator>
<dc:creator>Alexander Christian Falkentoft</dc:creator>
<dc:creator>Morten Malmborg</dc:creator>
<dc:creator>Nina Nouhravesh</dc:creator>
<dc:creator>Gunnar Gislason</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Christian Torp-Pedersen</dc:creator>
<dc:creator>Thomas S G Sehested</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Temporal Trends in Noncardiovascular Morbidity and Mortality Following Acute Myocardial Infarction</dc:title>
<dc:identifier>pmid:37648355</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.024</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648354/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):1051. doi: 10.1016/j.jacc.2023.07.009.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648354/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37648354</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.009>10.1016/j.jacc.2023.07.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648354</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:37648354</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.009</dc:identifier>
</item>
<item>
<title>Ablation to Reduce Atrial Fibrillation Burden and Improve Outcomes: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648353/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>Atrial fibrillation is the most common atrial arrhythmia and accounts for a significant burden of cardiovascular disease globally. With advances in implanted and wearable cardiac monitoring technology, it is now possible to readily and accurately quantify an individual's time spent in atrial fibrillation. This review summarizes the relationship between atrial fibrillation burden and adverse cardiovascular and cerebrovascular outcomes and discusses the role of catheter ablation to mitigate the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):1039-1050. doi: 10.1016/j.jacc.2023.06.029.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atrial fibrillation is the most common atrial arrhythmia and accounts for a significant burden of cardiovascular disease globally. With advances in implanted and wearable cardiac monitoring technology, it is now possible to readily and accurately quantify an individual's time spent in atrial fibrillation. This review summarizes the relationship between atrial fibrillation burden and adverse cardiovascular and cerebrovascular outcomes and discusses the role of catheter ablation to mitigate the morbidity and mortality associated with greater burden of atrial fibrillation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648353/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37648353</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.029>10.1016/j.jacc.2023.06.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648353</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Hannah T Schwennesen</dc:creator>
<dc:creator>Jason G Andrade</dc:creator>
<dc:creator>Kathryn A Wood</dc:creator>
<dc:creator>Jonathan P Piccini</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ablation to Reduce Atrial Fibrillation Burden and Improve Outcomes: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:37648353</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.029</dc:identifier>
</item>
<item>
<title>Impact of Sex on Cardiovascular Adaptations to Exercise: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648352/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>Routine exercise leads to cardiovascular adaptations that differ based on sex. Use of cardiac testing to screen athletes has driven research to define how these sex-based adaptations manifest on the electrocardiogram and cardiac imaging. Importantly, sex-based differences in cardiovascular structure and outcomes in athletes often parallel findings in the general population, underscoring the importance of understanding their mechanisms. Substantial gaps exist in the understanding of why...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):1030-1038. doi: 10.1016/j.jacc.2023.05.070.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Routine exercise leads to cardiovascular adaptations that differ based on sex. Use of cardiac testing to screen athletes has driven research to define how these sex-based adaptations manifest on the electrocardiogram and cardiac imaging. Importantly, sex-based differences in cardiovascular structure and outcomes in athletes often parallel findings in the general population, underscoring the importance of understanding their mechanisms. Substantial gaps exist in the understanding of why cardiovascular adaptations and outcomes related to exercise differ by sex because of underrepresentation of female participants in research. As female sports participation rates have increased dramatically over several decades, it also remains unknown if differences observed in older athletes reflect biological mechanisms vs less lifetime access to sports in females. In this review, we will assess the effect of sex on cardiovascular adaptations and outcomes related to exercise, identify the impact of sex hormones on exercise performance, and highlight key areas for future research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648352/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37648352</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.070>10.1016/j.jacc.2023.05.070</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648352</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Bradley J Petek</dc:creator>
<dc:creator>Eugene H Chung</dc:creator>
<dc:creator>Jonathan H Kim</dc:creator>
<dc:creator>Rachel Lampert</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:creator>Dermot Phelan</dc:creator>
<dc:creator>Alfred Danielian</dc:creator>
<dc:creator>Peter N Dean</dc:creator>
<dc:creator>Elizabeth H Dineen</dc:creator>
<dc:creator>Antonio B Fernandez</dc:creator>
<dc:creator>Mustafa Husaini</dc:creator>
<dc:creator>Sheela Krishnan</dc:creator>
<dc:creator>Ankit B Shah</dc:creator>
<dc:creator>Katie M Stewart</dc:creator>
<dc:creator>Meagan M Wasfy</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impact of Sex on Cardiovascular Adaptations to Exercise: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:37648352</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.070</dc:identifier>
</item>
<item>
<title>STEMI-Related Mortality: Don't Stop Believin'</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648351/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230901160807&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):1011-1013. doi: 10.1016/j.jacc.2023.07.007.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648351/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230901160807&v=2.17.9.post6+86293ac">37648351</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.007>10.1016/j.jacc.2023.07.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648351</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Timothy D Henry</dc:creator>
<dc:creator>Suzanne J Baron</dc:creator>
<dc:creator>Alice K Jacobs</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>STEMI-Related Mortality: Don't Stop Believin'</dc:title>
<dc:identifier>pmid:37648351</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.007</dc:identifier>
</item>





























</channel>
</rss>